NASDAQ:NTLA Lawsuit Alert: Investors Who Purchased Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) Should Contact the Shareholders Foundation
A lawsuit was filed for certain investors in Intellia Therapeutics, Inc. (NASDAQ:NTLA) shares. Investors who purchased shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) prior to July 2024 and continue to hold any of those NASDAQ:NTLA shares also have certain options and contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
SAN DIEGO, March 3, 2025 (Newswire.com) - The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in Intellia Therapeutics, Inc. (NASDAQ:NTLA) shares.
Investors who purchased shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) prior to July 2024 and continue to hold any of those NASDAQ:NTLA shares also have certain options and contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
On February 11, 2025, an investor in NASDAQ:NTLA shares filed a lawsuit against Intellia Therapeutics, Inc. over alleged securities laws violations. The plaintiff alleges that the defendants made false and/or misleading statements and/or failed to disclose that the defendants created the false impression that they possessed reliable information pertaining to the viability of NTLA-3001's development and eventual marketing, if approved, that Intellia's optimistic reports of timelines, including dosing and future studies of the drug, fell short of reality; the NTLA program was not viable or sustainable for Intellia because viral-based editing programs remained expensive and inefficient in comparison to then-existing non-viral delivery methods, that Intellia was not equipped to timely dose patients with NTLA-3001, maintain the drug's research and development, or even to maintain its full staff in light of the existing scientific landscape surrounding viral-based editing drugs, and that even if NTLA-3001 proved successful, the use of viral-based editing drugs is costly, inefficient, and poor mitigators of adverse effects in patients.
Those who purchased shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) should contact the Shareholders Foundation, Inc.
CONTACT:
Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
mail@shareholdersfoundation.com
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon
SOURCE: Shareholders Foundation, Inc.
Source: Shareholders Foundation, Inc.